영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
teva uk ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
sigma pharmaceuticals plc - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
actavis uk ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
mawdsley-brooks & company ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
zentiva pharma uk ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
alliance healthcare (distribution) ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
phoenix healthcare distribution ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
de pharmaceuticals - alfuzosin hydrochloride - oral tablet - 2.5mg
영국 -
영어 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
alfuzosin 2.5mg tablets
sandoz ltd - alfuzosin hydrochloride - oral tablet - 2.5mg
미국 -
영어 -
NLM (National Library of Medicine)
alfuzosin hydrochloride tablet, extended release
bryant ranch prepack - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride extended-release tablets, usp are indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride extended-release tablets, usp are not indicated for the treatment of hypertension. alfuzosin hydrochloride extended-release tablets, usp are not indicated for use in pediatric population. alfuzosin hydrochloride extended-release tablets are contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations(8.7) and clinical pharmacology (12.3)]. - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzo